Nezulcitinib

Names

[ Name ]:
Nezulcitinib

Biological Activity

[Description]:

Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation[1][2].

[Related Catalog]:

Signaling Pathways >> JAK/STAT Signaling >> JAK

Signaling Pathways >> Epigenetics >> JAK

Signaling Pathways >> Stem Cell/Wnt >> JAK

Research Areas >> Infection

Research Areas >> Inflammation/Immunology

[Target]

JAK

[In Vitro]

Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor[1][2].

[References]

[1]. Theravance's nezulcitinib fails to meet Phase II goals in Covid-19

[2]. Theravance biopharma, inc. Announces top-line results from phase 2 study of nezulcitinib in patients hospitalized with acute lung injury due to COVID-19

Chemical & Physical Properties

[ Molecular Formula ]:
C₃₀H₃₇N₇O₂

[ Molecular Weight ]:
527.66